PDF(Pubmed)
Abstract：
UNASSIGNED: Bevacizumab combined with fluorouracil is the currently recommended maintenance treatment for metastatic colorectal cancer, but the use of bevacizumab needs to be carried out in hospitals, which invisibly increases the risk of patients\' exposure to coronavirus disease 2019 (COVID-19) during the COVID-19 epidemic. Therefore, except of the advantage of convenience, all oral drugs as the maintenance treatment can reduce hospitalization and potential exposure risk during the COVID-19 epidemic, which is worth further exploration.
UNASSIGNED: First case was a 49-year-old male with stage IV colon adenocarcinoma and abnormal liver function who was given bevacizumab with FOLFOXIRI (8-cycles), following which his liver function recovered. Oxaliplatin was stopped upon thrombocytopenia development. The patient was finally maintained on oral fruquintinib and capecitabine therapy since November 2020, and has been progression-free for >15 months. Grade 2 leukopenia, neutropenia, and thrombocytopenia; grade 1 terminal nerve injury; and grade 1 hand and foot numbness were observed. The second case was a 48-year-old male with advanced colon cancer who underwent laparoscopic sigmoidectomy. Post-surgery, the patient was commenced on fluorouracil and leucovorin (1-cycle), followed by conversion therapy with cetuximab and chemotherapy (6-cycles). The patient underwent left hemi-hepatectomy, partial hepatectomy of the right lobe, and intraoperative radiofrequency ablation, following which he continued to receive cetuximab and chemotherapy. The patient was maintained on oral fruquintinib and capecitabine since December, 2020 and has been progression-free for >14 months. Grade1 myelosuppression, leukopenia, and neutropenia, grade 2 thrombocytopenia were observed.
UNASSIGNED: This case report based on preliminary evidence advocates oral fruquintinib-capecitabine maintenance treatment as an alternative to bevacizumab-capecitabine standard therapy for CRC patients, especially in the era of COVID-19 epidemic. This scheme can reduce hospitalization and potential COVID-19 contact, and is more convenient than intravenous administration. Which should be further explored in future studies.
UNASSIGNED: First case was a 49-year-old male with stage IV colon adenocarcinoma and abnormal liver function who was given bevacizumab with FOLFOXIRI (8-cycles), following which his liver function recovered. Oxaliplatin was stopped upon thrombocytopenia development. The patient was finally maintained on oral fruquintinib and capecitabine therapy since November 2020, and has been progression-free for >15 months. Grade 2 leukopenia, neutropenia, and thrombocytopenia; grade 1 terminal nerve injury; and grade 1 hand and foot numbness were observed. The second case was a 48-year-old male with advanced colon cancer who underwent laparoscopic sigmoidectomy. Post-surgery, the patient was commenced on fluorouracil and leucovorin (1-cycle), followed by conversion therapy with cetuximab and chemotherapy (6-cycles). The patient underwent left hemi-hepatectomy, partial hepatectomy of the right lobe, and intraoperative radiofrequency ablation, following which he continued to receive cetuximab and chemotherapy. The patient was maintained on oral fruquintinib and capecitabine since December, 2020 and has been progression-free for >14 months. Grade1 myelosuppression, leukopenia, and neutropenia, grade 2 thrombocytopenia were observed.
UNASSIGNED: This case report based on preliminary evidence advocates oral fruquintinib-capecitabine maintenance treatment as an alternative to bevacizumab-capecitabine standard therapy for CRC patients, especially in the era of COVID-19 epidemic. This scheme can reduce hospitalization and potential COVID-19 contact, and is more convenient than intravenous administration. Which should be further explored in future studies.
摘要：
UNASSIGNED：贝伐单抗联合氟尿嘧啶是目前推荐的转移性结直肠癌维持治疗，但是贝伐单抗的使用需要在医院进行，这无形中增加了患者在COVID-19流行期间接触2019年冠状病毒病（COVID-19）的风险。因此,除了方便的优势，所有口服药物作为维持治疗可以减少COVID-19流行期间的住院和潜在暴露风险，值得进一步探讨。
UNASSIGNED：首例是一名49岁男性，患有IV期结肠腺癌和肝功能异常，接受贝伐单抗联合FOLFOXIRI（8个周期），之后他的肝功能恢复了.在血小板减少症发展时停用奥沙利铂。自2020年11月以来，患者最终维持口服氟喹替尼和卡培他滨治疗，并且在超过15个月内无进展。2级白细胞减少症,中性粒细胞减少症,血小板减少；1级末端神经损伤；1级手足麻木。第二例是一名48岁的男性，患有晚期结肠癌，他接受了腹腔镜乙状结肠切除术。手术后,患者开始服用氟尿嘧啶和亚叶酸（1个周期），随后是西妥昔单抗和化疗的转换治疗（6个周期）。患者接受左半肝切除术,右叶部分肝切除术,术中射频消融，之后他继续接受西妥昔单抗和化疗.患者自12月以来一直口服氟喹替尼和卡培他滨，2020年，已经超过14个月无进展。Grade1骨髓抑制，白细胞减少症,和中性粒细胞减少症,观察到2级血小板减少.
UNASSIGNED：该病例报告基于初步证据，主张口服氟喹替尼-卡培他滨维持治疗，替代贝伐单抗-卡培他滨标准治疗，用于CRC患者。尤其是在COVID-19流行的时代。该方案可以减少住院和潜在的COVID-19接触，比静脉给药更方便。这在今后的研究中应进一步探讨。
UNASSIGNED：首例是一名49岁男性，患有IV期结肠腺癌和肝功能异常，接受贝伐单抗联合FOLFOXIRI（8个周期），之后他的肝功能恢复了.在血小板减少症发展时停用奥沙利铂。自2020年11月以来，患者最终维持口服氟喹替尼和卡培他滨治疗，并且在超过15个月内无进展。2级白细胞减少症,中性粒细胞减少症,血小板减少；1级末端神经损伤；1级手足麻木。第二例是一名48岁的男性，患有晚期结肠癌，他接受了腹腔镜乙状结肠切除术。手术后,患者开始服用氟尿嘧啶和亚叶酸（1个周期），随后是西妥昔单抗和化疗的转换治疗（6个周期）。患者接受左半肝切除术,右叶部分肝切除术,术中射频消融，之后他继续接受西妥昔单抗和化疗.患者自12月以来一直口服氟喹替尼和卡培他滨，2020年，已经超过14个月无进展。Grade1骨髓抑制，白细胞减少症,和中性粒细胞减少症,观察到2级血小板减少.
UNASSIGNED：该病例报告基于初步证据，主张口服氟喹替尼-卡培他滨维持治疗，替代贝伐单抗-卡培他滨标准治疗，用于CRC患者。尤其是在COVID-19流行的时代。该方案可以减少住院和潜在的COVID-19接触，比静脉给药更方便。这在今后的研究中应进一步探讨。
